ArchiveJanuary 2012

Drinking alcohol and MS

Epub: Foster et al. Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol. 2012 Jan. OBJECTIVE: To examine the associations of alcohol consumption patterns with disability and brain injury in MS’ers. DESIGN: This study included 423 subjects (272 MS’ers, 151 healthy controls) participating in a study of clinical, environmental...

Are you on natalizumab (Tysabri)? Do you know your JCV status?

Epub ahead of print:  Fox & Rudick. Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology. 2012 Jan 25.   Natalizumab has demonstrated efficacy in multiple sclerosis (MS), but is associated with increased risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection caused by the JC virus. At the...

Research: Viral Trigger of Relapse

Laska MJ, Brudek T, Nissen KK, Christensen T, Anné ML, Petersen T, Nexø BA. Expression of HERV-Fc1, a human endogenous retrovirus, is increased in patients with active Multiple Sclerosis. J Virol. 2012 Jan.[Epub ahead of print] Multiple Sclerosis (MS) is considered to be an autoimmune disease with unknown cause and with immune system dysregulation. Among environmental factors, viruses are most...

Research: Virus Causing autoimmunity

Libbey JE, Cusick MF, Tsunoda I, Fujinami RS. Antiviral CD8(+) T cells cause an experimental autoimmune encephalomyelitis-like disease in naive mice. J Neurovirol. 2012 Jan 27. [Epub ahead of print] Major histocompatibility complex class I-restricted CD8(+) cytotoxic T lymphocytes are involved in the pathogenesis of multiple sclerosis (MS) and both autoimmune, experimental autoimmune...

Research: Monitoring Progression

Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G. Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis.Autoimmunity. 2012 Jan 26. [Epub ahead of print] Monitoring neuroaxonal loss in multiple sclerosis is an important objective to study the pathogenesis and response to treatment of the disease. The release of neurofilaments is a potential surrogate...

Bad Science:Interferons after Mitoxantrone

Today is our research day and I have to deliver Bad Science. When you read papers you have to digest whether they actually tell us anything. You do not always believe things you read. Importantly is it worth reading them in the first place? Todays story is an an example. NO LINK PROVIDED, READING VALUE IS LOW Objective: The objective of this study was to assess the effect of treatment with...

Bad Refereeing: New model for Progression

Normally I do not report on animal models of MS but as Mouse Doc is doing “Bad Science Day” at our research Day and the media have found that “Diabetic mice have provided a surprising breakthrough for MS research 1:5:2012″ todays new breakthrough extends this further. We have been talking about the publication process. Part of this is the independent review process. The...

Research Beta Interferon does not stop secondary Progressive MS

La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, Filippini G. Interferon beta for secondary progressive multiple sclerosis.Cochrane Database Syst Rev. 2012 Jan;1:CD005181. BACKGROUND: Therapy with either recombinant beta-1a or beta-1b interferons (IFNs) is worldwide approved for Relapsing Remitting Multiple Sclerosis (RRMS). A major unanswered question is whether this...

Translate

Categories

Recent Posts

Recent Comments

Archives